Sun, Sep-08-02, 12:43
|
 |
Forum Founder
Posts: 37,432
|
|
Plan: LC, GF
Stats: 241/190/140
BF:
Progress: 50%
Location: Eastern ON, Canada
|
|
Quote:
|
On September 16, 1997, under pressure from the Food and Drug Administration (FDA), concerned medical authorities and injured diet drugs patients who had filed lawsuits, American Home Products, the manufacturer of the diet drugs Pondimin (fenfluramine) and Redux (dexfenfluramine), took the drugs off the market. In January 2002, a nationwide class action settlement with American Home Products received final judicial approval.
|
Quote:
Fen Phen Patients with Mitral Valve Regurgitation or Aortic Valve Regurgitation
Under the class action matrix compensation program, qualifying damage most commonly involves (1) moderate or above mitral valve regurgitation and/or moderate or above aortic valve regurgitation and qualifying complications (such as qualifying levels of left atrial enlargement, ejection fraction, pulmonary hypertension and others), and/or (2) persons who undergo mitral or aortic valve repair or valve surgery, and such persons can submit potential claims for thousands, hundreds of thousands or one million dollars or more in matrix compensation benefits, depending on their individual damages.
|
For more information, check out: Doreen
|